Empagliflozin in heart failure with a preserved ejection fraction
Abstract: Background: Sodium–glucose cotransporter 2 inhibitors reduce the risk of hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, but their effects in patients with heart failure and a preserved ejection fraction are uncertain. Methods: In this double-blind trial, we randomly assigned 5988 patients with class II–IV heart failure and an ejection fraction of more than 40% to receive empagliflozin (10 mg once daily) or placebo, in addition to usual therapy. The primary outcome was a composite of cardiovascular death or hospitalization for heart failure. Results: Over a median of 26.2 months, a primary outcome event occurred in 415 of 2997 patients (13.8%) in the empagliflozin group and in 511 of 2991 patients (17.1%) in the placebo group (hazard ratio, 0.79; 95% confidence interval [CI], 0.69 to 0.90; P<0.001). This effect was mainly related to a lower risk of hospitalization for heart failure in the empagliflozin group. The effects of empagliflozin appeared consistent in patients with or without diabetes. The total number of hospitalizations for heart failure was lower in the empagliflozin group than in the placebo group (407 with empagliflozin and 541 with placebo; hazard ratio, 0.73; 95% CI, 0.61 to 0.88; P<0.001). Uncomplicated genital and urinary tract infections and hypotension were reported more frequently with empagliflozin.
Similar Items
-
Revista Ecuatoriana de Medicina y Ciencias Biológicas, vol 03 - No. 02
by: Casa de la Cultura Ecuatoriana
Published: (2017-05-03T20:00:39Z) -
Aspectos nutricionales de las cardiopatías
by: Di Tollo, B.A. -
Prevalencia de Síndrome Cardiorrenal en pacientes hospitalizados por Insuficiencia cardíaca descompensada
by: Otaduy, Cintia, et al.
Published: (2013) -
Diseño de una formulación farmacéutica de Betametildigoxina para el tratamiento de la insuficiencia cardíaca congestiva como una alternativa accesible, en términos de calidad y precio, para la población afectada por esta patología de alta incidencia. Version 31-08-2013.
by: Rodríguez Arroyo, Nelson
Published: (2019-12-28T13:37:27Z) -
El lisinopril en el tratamiento de la insuficiencia cardíaca congestiva canina
by: Lightowler, C.H.